Nicolas Gendron on The Emerging Role of CLIA in The Diagnosis Strategy for HIT
Nicolas Gendron, Research Fellow, Hematologist at Boston Children’s Hospital, shared a proud post on LinkedIn:
”New online publication in Blood VTH, Blood Journals Portfolio
Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin treatments.
Its rapid and reliable diagnosis is essential to adapt management and improve the prognosis of patients.
At the HEGP, we compared the diagnostic performance for the detection of anti-PF4/H antibodies of the HemosIL AcuStar HIT-IgG test (CLIA, Werfen ) with that of our Zymutest HIA IgG reference test (ELISA, HYPHEN BioMed ), in 113 patients suspected of TIH (score 4Ts >3), taking as a reference the result of the platelet function test by radiolabeled serotonin release (RAS).
Excellent sensitivity and specificity of both tests
- Very few discordant cases among patients with confirmed HIT
- Overall agreement between the two techniques: 91.2%
- CLIA has proven to be reliable, fast and efficient
These findings support the use of CLIA as a rapid and relevant diagnostic tool in the diagnosis strategy for HIT
Congratulations to Carla Rial and everyone involved in this great collaborative work!
Shaya Sable, Christine Le Beller, Aurélie Sarthou, Mauge Laetitia, Justine Piazza, Roya Nili Maude Laney, Isabelle Presot Jean-Luc Diehl, Agnès Lillo-Le Louet, Anne Godier, David Smadja, Helley-Russick Dominique
Paris Cardiovascular Research Center – PARCC
Université Paris Cité Faculté de Santé – Université Paris Cité
Université Paris Cité Médecine Greater Paris University Hospitals – AP-HP
Werfen Werfen North America”
Read the full article in Blood VTH.
Article: Evaluation of a chemiluminescent immunoassay IgG anti-PF4/H in the Diagnosis of Heparin-Induced Thrombocytopenia
Authors: Carla Rial, Nicolas Gendron, Christine Le Beller, Shaya Sable, Aurélie Sarthou, Laetitia Mauge, Justine Piazza, Roya Nili, Maude Laney, Isabelle Presot, Jean-Luc Diehl, Anne Godier, Agnès Lillo-Le Louet, David M. Smadja, Dominique Helley
Stay updated on the latest scientific advances in the field of platelet disorders with Hemostasis Today.
-
Oct 27, 2025, 12:12Maria Roussakis: It is an Honour to Be a Part of the ISBT Young Professionals Council
-
Oct 27, 2025, 05:47Ahmed Koriesh on The Novel Approach in Use of Tenecteplase
-
Oct 27, 2025, 04:42Louise Breslin: Exciting Results in The CRYPTICS Trial
-
Oct 26, 2025, 16:55ECTH 2025: 3 Unforgettable Days of Science and Shared Purpose
-
Oct 26, 2025, 16:35Ahmed Koriesh on Thrombolysis in Stroke Patients on DOACs
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 27, 2025, 05:00Wolfgang Miesbach on WFH Guidelines Covering FDA/EMA-Approved AAV Gene Therapy for Hemophilia
-
Oct 26, 2025, 15:04Nita Radhakrishnan and Colleagues on Inherited Haematological Conditions
-
Oct 26, 2025, 14:55Anirban Sen Gupta on Biosynthetic Blood Surrogates Current State-of-Art
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation
-
Oct 27, 2025, 06:30Andres Ricaurte Fajardo on CVT Experience from a Latin American Cohort